Home › Funds › Rosalind Advisors, Inc. › ABVX
Rosalind Advisors, Inc. position in ABVX
ABIVAX SA · Health Care
Rosalind Advisors, Inc. reported holding 20,869 shares of ABVX (ABIVAX SA) in its Q2 2026 13F filing — a position valued at US$2.8M, representing 1.03% of its reported portfolio and ranking #20 among its reported holdings. Rosalind Advisors, Inc. has disclosed ABVX holdings in 4 of the last 10 reported quarters, going back to Q1 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Rosalind Advisors, Inc.'s ABVX position evolved
Rosalind Advisors, Inc. first disclosed a stake in ABVX in Q1 2024 at 378,416 shares (US$5.4M). Across 4 filings, Rosalind Advisors, Inc. increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 20,869 shares valued at US$2.8M. Notable position changes include a 63% trim in Q3 2024 (shares fell 36% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 378.42K | $5.41M | New |
| Q2 2024 | 378.42K | $5.00M | Hold |
| Q3 2024 | 139.98K | $1.61M | Reduce |
| Q2 2026 | 20.87K | $2.78M | New |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ABVX and 13F data
ABVX (ABIVAX SA) is a Health Care company. 73 other funds we track also report a position in ABVX — the largest reported positions include TCG Crossover Management, LLC (US$800.6M), Helikon Investments Ltd (US$371.4M), Darwin Global Management, Ltd. (US$348.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ABVX
- TCG Crossover Management, LLC 6.01M sh · $800.60M · Q2 2026
- Helikon Investments Ltd 2.79M sh · $371.41M · Q2 2026
- Darwin Global Management, Ltd. 3.62M sh · $348.22M · Q2 2026
- Vestal Point Capital, LP 2.35M sh · $313.09M · Q2 2026
- Caligan Partners LP 1.56M sh · $207.61M · Q2 2026
- WESTFIELD CAPITAL MANAGEMENT CO LP 1.31M sh · $174.55M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 1.13M sh · $150.92M · Q2 2026
- Logos Global Management LP 1.02M sh · $136.46M · Q2 2026
- Octagon Capital Advisors LP 993.00K sh · $132.33M · Q2 2026
- Eversept Partners, LP 913.88K sh · $121.78M · Q2 2026
- Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. 765.33K sh · $101.99M · Q2 2026
- Cormorant Asset Management, LP 675.00K sh · $89.95M · Q2 2026
More on Rosalind Advisors, Inc.
FAQ
How long has Rosalind Advisors, Inc. held ABVX?
Rosalind Advisors, Inc. has disclosed ABVX holdings in 4 of the last 10 reported quarters, going back to Q1 2024.
What is Rosalind Advisors, Inc.'s current position in ABVX?
As of Q2 2026, Rosalind Advisors, Inc. holds 20.87K shares of ABVX (ABIVAX SA), valued at $2.78M, representing 1.03% of its reported portfolio and ranking #20.
Has Rosalind Advisors, Inc. been buying or selling ABVX?
In the latest 13F filing (Q2 2026), Rosalind Advisors, Inc. newly opened its position in ABVX.
Which other funds hold ABVX?
Other major institutional holders of ABVX include TCG Crossover Management, LLC, Helikon Investments Ltd, Darwin Global Management, Ltd., among 73 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.